Inhibrx Biosciences, Inc. (INBX)
NASDAQ: INBX · Real-Time Price · USD
14.60
+0.72 (5.19%)
Dec 20, 2024, 4:00 PM EST - Market closed
Inhibrx Biosciences Employees
As of December 31, 2023, Inhibrx Biosciences had 172 total employees, including 166 full-time and 6 part-time employees.
Employees
172
Change
n/a
Growth
n/a
Revenue / Employee
$9,116
Profits / Employee
$10,047,849
Market Cap
211.35M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 172 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Inogen | 834 |
| SOPHiA GENETICS | 430 |
| MacroGenics | 339 |
| ADC Therapeutics | 274 |
| Inventiva | 123 |
| Atai Life Sciences | 83 |
| Lexeo Therapeutics | 58 |
| DiaMedica Therapeutics | 19 |
INBX News
- 5 weeks ago - Inhibrx Biosciences Reports Third Quarter 2024 Financial Results - PRNewsWire
- 6 weeks ago - Inhibrx Biosciences: Reincorporated And Trying To Find A Niche With Unique Platform - Seeking Alpha
- 6 weeks ago - Inhibrx Prevails in Trade Secret Case, Reaffirming Its Commitment to Integrity and Innovation - PRNewsWire
- 4 months ago - Over $7M Bet On This Health Care Stock? Check Out These 3 Stocks Executives Are Buying - Benzinga
- 4 months ago - Inhibrx Biosciences Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights - PRNewsWire
- 7 months ago - Inhibrx: Continued Advancement Even After INBRX-101 Sale To Sanofi - Seeking Alpha
- 7 months ago - Top 4 Health Care Stocks That Are Preparing To Pump This Month - Inhibrx Biosciences (NASDAQ:INBX) - Benzinga
- 7 months ago - Inhibrx Inc. Stockholders Approve Sale of INBRX-101 to Sanofi - PRNewsWire